Drug-Eluting Stents for Saphenous Vein Graft Lesions. The Limits of Evidence

Journal of the American College of Cardiology

Volumn 53, Issue 11, 2009, Pages 929-930

  Bittl, John A ^a  

^a Munroe Regional Med Center   (United States)

Author keywords

atherosclerosis; randomized trials; restenosis

Indexed keywords

PACLITAXEL; RAPAMYCIN;

BARE METAL STENT; BIOASSAY; CORONARY ARTERY BYPASS GRAFT; DRUG ELUTING STENT; EDITORIAL; FOLLOW UP; HUMAN; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RESTENOSIS; RETROSPECTIVE STUDY; SAPHENOUS VEIN; SURVIVAL RATE; TREATMENT OUTCOME; VEIN GRAFT DISEASE;

CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; HUMANS; PACLITAXEL; SAPHENOUS VEIN;

EID: 61549126939     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.12.011     Document Type: Editorial

References (15)

1. Brilakis E.S., Lichtenwalter C., de Lemos J.A., et al. A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions: the SOS (Stenting Of Saphenous Vein Grafts) trial. J Am Coll Cardiol 53 (2009) 919-928
2. Vermeersch P., Agostoni P., Verheye S., et al. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial. J Am Coll Cardiol 48 (2006) 2423-2431
3. Vermeersch P., Agostoni P., Veryheye S., et al. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC trial. J Am Coll Cardiol 50 (2007) 261-270
4. Brilakis E.S., and Berger P.B. Should bare metal or drug-eluting stents be used during PCI of saphenous vein graft lesions: waiting for Godot?. Catheter Cardiovasc Interv 72 (2008) 815-818
5. Gioia G., Bennassi A., Mohendra R., Chowdhury K., Massood I., and Matthai W. Lack of clinical long-term benefit with the use of a drug eluting stent compared to use of a bare metal stent in saphenous vein grafts. Catheter Cardiovasc Interv 72 (2008) 13-20
6. Brodie B.R., Stuckey T., Downey W., et al. Outcomes and complications with off-label use of drug-eluting stents: results from STENT (Strategic Transcatheter Evaluation of New Therapies) Group. J Am Coll Cardiol Interv 1 (2008) 405-415
7. Savage M.P., Douglas J.S., Fischman D.L., et al. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. N Engl J Med 337 (1997) 740-747
8. Ratliff N.B., and Myles J.L. Rapidly progressive atherosclerosis in aortocoronary saphenous vein grafts: possible immune-mediated disease. Arch Pathol Lab Med 113 (1989) 772-776
9. Ribichini F., Pugno F., Ferrero V., et al. Long-term histological and immunohistochemical findings in human venous aorto-coronary bypass grafts. Clin Sci (Lond) 114 (2008) 211-220
10. Waksman R., Ajani A.E., White R.L., et al. Intravascular gamma radiation for in-stent restenosis in saphenous-vein bypass grafts. N Engl J Med 346 (2002) 1194-1199
11. Hoffman R., Hamm C., Nienaber C.A., et al. Implantation of sirolimus-eluting stents in saphenous vein grafts is associated with high clinical follow-up event rates compared with treatment of native vessels. Coron Artery Dis 18 (2007) 559-564
12. Ellis S.G., Brener S.J., DeLuca S., et al. Late myocardial ischemic events after saphenous vein graft intervention-importance of initially "nonsignificant" vein graft lesions. Am J Cardiol 79 (1997) 1460-1464
13. Serruys P., de Jaegere P., Kiemeneij F., et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 331 (1994) 489-495
14. Fischman D.L., Leon M.B., Baim D.S., et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 331 (1994) 496-501
15. Kolata G. New arena for testing of drugs: real world. New York Times. New York edition, vol. CLVIII, 2008:D1.